Rule 2.7, 3.10.3, 3.10.4, 3.10.5

# Appendix 3B

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

Avira Resources Limited

ABN 38 131 715 645

We (the entity) give ASX the following information.

#### Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1 <sup>+</sup>Class of <sup>+</sup>securities issued or to be issued

(i) and (ii): Fully Paid Ordinary Shares (**Shares**) (iii) Options

- 2 Number of \*securities issued or to be issued (if known) or maximum number which may be issued
- 3 Principal terms of the \*securities (e.g. if options, exercise price and expiry date; if partly paid \*securities, the amount outstanding and due dates for payment; if \*convertible securities, the conversion price and dates for conversion)

(i)	87,088,295
(ii)	170,823,410
(iii)	50,000,000

(i) and (ii): Shares (iii) Options

+ See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	(i) and (ii): Yes (iii) No
	<ul> <li>If the additional *securities do not rank equally, please state:</li> <li>the date from which they do</li> <li>the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul>	
5	Issue price or consideration	(i) and (ii): \$0.003 per Share (iii) \$0.0001 per Corporate Advisor Option
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	<ul> <li>(i) and (ii): Repayment of debt, evaluation of the Company's existing minerals assets and working capital</li> <li>(iii) Corporate Advisor Options issued following approval by shareholders at the general meeting held on 22 December 2017</li> </ul>
6a	Is the entity an <sup>+</sup> eligible entity that has obtained security holder approval under rule 7.1A?	Yes
	If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i	
6b	The date the security holder resolution under rule 7.1A was passed	30 November 2017
6c	Number of <sup>+</sup> securities issued without security holder approval under rule 7.1	Nil
6d	Number of <sup>+</sup> securities issued with security holder approval under rule 7.1A	Nil

<sup>+</sup> See chapter 19 for defined terms.

6e	Number of <sup>+</sup> securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	Company's placement a November 2017 as appr the general meeting held 50,000,000 Corporate	Advisor Options issued areholders at the general
6f	Number of <sup>+</sup> securities issued under an exception in rule 7.2		sued pursuant to the offer announced to ASX
6g	If <sup>+</sup> securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the <sup>+</sup> issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If <sup>+</sup> securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	7.1: 51,750,000 7.1A: 34,500,000	
7	<sup>+</sup> Issue dates	3 January 2018	
	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.	, , , , , , , , , , , , , , , , , , ,	
	Cross reference: item 33 of Appendix 3B.		
		Number	+Class
8	Number and <sup>+</sup> class of all		01033
-	<sup>+</sup> securities quoted on ASX	345,000,000	Shares

(including the \*securities in

section 2 if applicable)

<sup>+</sup> See chapter 19 for defined terms.

		Number	+Class
9	Number and <sup>+</sup> class of all <sup>+</sup> securities not quoted on ASX ( <i>including</i> the <sup>+</sup> securities in section 2 if applicable)		Unquoted options exercisable at \$0.01 each on or before 16th September 2021. (For more information refer to the Company's notice of general meeting for the meeting held on 16 September 2016)
		50,000,000	Unquoted options exercisable at \$0.01 each on or before 31 December 2019. (For more information refer to the Company's notice of general meeting for the meeting held on 22 December 2017)

10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

N/A – the Company does not have a dividend policy.

# Part 2 - Pro rata issue

11	Is security holder approval required?
12	Is the issue renounceable or non- renounceable?
13	Ratio in which the <sup>+</sup> securities will be offered
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates
15	<sup>+</sup> Record date to determine entitlements
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?
17	Policy for deciding entitlements in relation to fractions

<sup>+</sup> See chapter 19 for defined terms.

18 Names of countries in which the entity has security holders who will not be sent new offer documents

> Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.

19 Closing date for receipt of acceptances or renunciations

<sup>+</sup> See chapter 19 for defined terms.

#### Appendix 3B New issue announcement

20	Names of any underwriters
21	Amount of any underwriting fee or commission
22	Names of any brokers to the issue
23	Fee or commission payable to the broker to the issue
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders
25	If the issue is contingent on security holders' approval, the date of the meeting
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders
28	Date rights trading will begin (if applicable)
29	Date rights trading will end (if applicable)
30	How do security holders sell their entitlements <i>in full</i> through a broker?
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?

<sup>+</sup> See chapter 19 for defined terms.

- 32 How do security holders dispose of their entitlements (except by sale through a broker)?
- 33 <sup>+</sup>Issue date

### Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

- 34 Type of <sup>+</sup>securities (*tick one*)
- (a)

#### <sup>+</sup>Securities described in Part 1<sup>A</sup>

<sup>A</sup> Only Fully paid ordinary shares issued as per (i) and (ii) to be quoted.

(b) [

All other <sup>+</sup>securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

#### Entities that have ticked box 34(a)

#### Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

10,001 - 100,000 100,001 and over

35

36

- If the \*securities are \*equity securities, the names of the 20 largest holders of the additional \*securities, and the number and percentage of additional \*securities held by those holders
- If the \*securities are \*equity securities, a distribution schedule of the additional \*securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000

37

A copy of any trust deed for the additional <sup>+</sup>securities

<sup>+</sup> See chapter 19 for defined terms.

#### Entities that have ticked box 34(b)

- 38 Number of <sup>+</sup>securities for which <sup>+</sup>quotation is sought
- 39 +Class of +securities for which quotation is sought
- 40 Do the <sup>+</sup>securities rank equally in all respects from the <sup>+</sup>issue date with an existing <sup>+</sup>class of quoted <sup>+</sup>securities?

If the additional <sup>+</sup>securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment
- 41 Reason for request for quotation now

Example: In the case of restricted securities, end of restriction period

(if issued upon conversion of another <sup>+</sup>security, clearly identify that other <sup>+</sup>security)

42 Number and <sup>+</sup>class of all <sup>+</sup>securities quoted on ASX (*including* the <sup>+</sup>securities in clause 38)

Number	+Class

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>1</sup> <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.
- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: .....

(Director)

Date: 3 January 2018

Print name: Mr Gary Kuo

== == == == ==

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3B – Annexure 1

# Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
<i>Insert</i> number of fully paid <sup>+</sup> ordinary securities on issue 12 months before the <sup>+</sup> issue date or date of agreement to issue	48,306,640	
Add the following:		
<ul> <li>Number of fully paid <sup>+</sup>ordinary securities issued in that 12 month period under an exception in rule 7.2</li> </ul>	27,021,655 Shares (issued on 11 October 2017 under exception 4 of LR 7.2 following the conversion of convertible redeemable preference shares issued on 16 September 2016 (18,181,820) with prior approval of shareholders obtained on 26 September 2017 and on 26 September 2017 (8,839,835) with prior approval of shareholders on 26 September 2017.	
	87,088,295 Shares (issued on 3 January 2018 under exceptions 1 and 3 of LR 7.2 pursuant to an entitlement issue and shortfall offer made under an offer document dated 5 December 2017).	
<ul> <li>Number of fully paid <sup>+</sup>ordinary securities issued in that 12 month period with shareholder approval</li> </ul>	7,200,000 (issued on 2 August 2017 and ratified by shareholders on 26 September 2017).	
	4,560,000 Shares (issued on 3 October 2017 and ratified by shareholders on 30 November 2017).	
	170,823,410 Shares (issued on 3 January 2018 as approved by shareholders on 22 December 2017).	
<ul> <li>Number of partly paid <sup>+</sup>ordinary securities that became fully paid in that 12 month period</li> </ul>	Nil	

<sup>+</sup> See chapter 19 for defined terms.

<ul> <li>Note:</li> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	
<b>Subtract</b> the number of fully paid <sup>+</sup> ordinary securities cancelled during that 12 month period	Nil
"A"	345,000,000

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"	
"В"	0.15
	[Note: this value cannot be changed]
<i>Multiply</i> "A" by 0.15	51,750,000
Step 3: Calculate "C", the amount 7.1 that has already been used	of placement capacity under rule
<i>Insert</i> number of <sup>+</sup> equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:	Nil
Under an exception in rule 7.2	
Under rule 7.1A	
• With security holder approval under rule 7.1 or rule 7.4	
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	
" <b>C</b> "	Nil
Step 4: Subtract "C" from ["A" x "L placement capacity under rule 7.1	3"] to calculate remaining
"A" x 0.15	51,750,000
Note: number must be same as shown in Step 2	
Subtract "C"	Nil
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.15] – "C"	51,750,000 [Note: this is the remaining placement capacity under rule 7.1]

<sup>+</sup> See chapter 19 for defined terms.

# Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
" <b>A</b> "	345,000,000	
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
<i>Multiply</i> "A" by 0.10	34,500,000	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
<i>Insert</i> number of <sup>+</sup> equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	Nil	
<ul> <li>Notes:</li> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
"E"	Nil	

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10	34,500,000	
Note: number must be same as shown in Step 2		
Subtract "E"	Nil	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.10] – "E"	34,500,000	
	Note: this is the remaining placement capacity under rule 7.1A	

<sup>+</sup> See chapter 19 for defined terms.



#### NOTICE UNDER SECTION 708A(5)(e) OF THE CORPORATIONS ACT

On 3 January 2018, Avira Resources Limited (ASX: AVW) (Company) completed the issue by way of a placement of 170,823,410 fully paid ordinary shares in the capital of the Company (Shares) at a price of \$0.003 per Share to clients of Cicero Advisory Services Pty Ltd (Placement).

The Company further completed, on 3 January 2018, the issue of 50,000,000 Options at an issue price of \$0.0001 per Option to nominees of Cicero Advisory Services Pty Ltd (Option Issue).

The Placement and Option Issue were previously announced on 8 November 2017 and shareholder approval was obtained at the Company's general meeting held on 22 December 2017.

The Company gives notice pursuant to section 708A(5)(e) of the Corporations Act 2001 (Cth) (Corporations Act) that:

- 1. the Company issued the Shares and Options without disclosure under Part 6D.2 of the Corporations Act; and
- 2. as at the date of this notice, the Company has complied with:
  - (a) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
  - (b) section 674 of the Corporations Act; and
- 3. as at the date of this notice, there is no information to be disclosed which is excluded information (as defined in section 708A(7) of the Corporations Act) that is reasonable for investors and their professional advisers to expect to find in a disclosure document.

# ASX RELEASE

3 January 2018

ASX CODE

AVW

#### REGISTRY

Computershare

#### SHARES ON ISSUE

345,000,000

#### Avira Resources Limited

Suite 4, Level 2, 189 Kent Street Sydney NSW 2000 Australia

T: 61 2 9262 1122 F: 61 2 9299 5175

www.mgt.net.au admin@aviraenergy.com

ABN: 38 131 715 645